A blood-based test for epidermal growth factor receptor mutations in lung cancer -: Commentary

被引：11

作者：

Bell, Daphne W.

Haber, Daniel A.

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA

[2] Harvard Med Sch, Charlestown, MA USA

来源：

CLINICAL CANCER RESEARCH | 2006年 / 12卷 / 13期

关键词：

D O I：

10.1158/1078-0432.CCR-06-0670

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3875 / 3877

页数：3

共 16 条

[1]

CHANG C, 2006, FILM COMMENT, V42, P17

[2] The development of imatinib as a therapeutic agent for chronic myeloid leukemia [J].

Deininger, M ;

Buchdunger, E ;

Druker, BJ .

BLOOD, 2005, 105 (07) :2640-2653

[3] Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib [J].

Han, SW ;

Kim, TY ;

Hwang, PG ;

Jeong, S ;

Kim, J ;

Choi, IS ;

Oh, DY ;

Kim, LH ;

Kim, DW ;

Chung, DH ;

Im, SA ;

Kim, YT ;

Lee, JS ;

Heo, DS ;

Bang, YJ ;

Kim, NK .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2493-2501

[4] A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma [J].

Haneda, H ;

Sasaki, H ;

Lindeman, N ;

Kawano, O ;

Endo, K ;

Suzuki, E ;

Shimizu, S ;

Yukiue, H ;

Kobayashi, Y ;

Yano, M ;

Fujii, Y .

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (02) :69-75

[5] Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer [J].

Kimura, Hideharu ;

Kasahara, Kazuo ;

Kawaishi, Makoto ;

Kunitoh, Hideo ;

Tamura, Tomohide ;

Holloway, Brian ;

Nishio, Kazuto .

CLINICAL CANCER RESEARCH, 2006, 12 (13) :3915-3921

[6] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].

Kobayashi, S ;

Boggon, TJ ;

Dayaram, T ;

Janne, PA ;

Kocher, O ;

Meyerson, M ;

Johnson, BE ;

Eck, MJ ;

Tenen, DG ;

Halmos, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792

[7] Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib [J].

Kwak, EL ;

Sordella, R ;

Bell, DW ;

Godin-Heymann, N ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Driscoll, DR ;

Fidias, P ;

Lynch, TJ ;

Rabindran, SK ;

McGinnis, JP ;

Wissner, A ;

Sharma, SV ;

Isselbacher, KJ ;

Settleman, J ;

Haber, DA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (21) :7665-7670

[8] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[9] Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence [J].

Mitsudomi, T ;

Kosaka, T ;

Endoh, H ;

Horio, Y ;

Hida, T ;

Mori, S ;

Hatooka, S ;

Shinoda, M ;

Takahashi, T ;

Yatabe, Y .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (11) :2513-2520

[10] Circulating tumor cells: the 'leukemic phase' of solid cancers [J].

Mocellin, S ;

Keilholz, U ;

Rossi, CR ;

Nitti, D .

TRENDS IN MOLECULAR MEDICINE, 2006, 12 (03) :130-139

← 1 2 →